Multilateral development banks

DGAP-News: Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Retrieved on: 
Monday, September 6, 2021
European Union, Sodium channel blockers, Drugs, Multilateral development banks, Financial services, Calcium channel blockers, Monoamine oxidase inhibitors, Economy of the European Union, InvestEU, Zambon, Safinamide, European Investment Bank

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
  • Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company's development programs in diseases of the central nervous system.
  • The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Retrieved on: 
Monday, September 6, 2021
Professional Services, Mental Health, Health, Finance, Pharmaceutical, Biotechnology, European Union, Multilateral development banks, Sodium channel blockers, Drugs, Financial services, Calcium channel blockers, Monoamine oxidase inhibitors, Economy of the European Union, InvestEU, Safinamide, European Investment Bank, Zambon

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
  • Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Companys development programs in diseases of the central nervous system.
  • The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

iAngels Ventures Raises $55.5M (€47M) for First Institutional Fund Anchored by the European Investment Fund Bringing Total AUM to over $300M (€255M)

Retrieved on: 
Tuesday, July 27, 2021
European Union, Multilateral development banks, Financial services, Finance, European Investment Bank, European Investment Fund

"We are well-positioned now to lead rounds and provide significant support to our companies from inception to exit.

Key Points: 
  • "We are well-positioned now to lead rounds and provide significant support to our companies from inception to exit.
  • Our investment is reinforcing the links between Israel and the European Union, and will result in strengthened cooperation in the research, development and innovation sphere."
  • The General Partners of iAngels Ventures include iAngels founders Hod Moyal and Assia, as well as iAngels Chairman David Assia .
  • The European Investment Fund (EIF) is part of the European Investment Bank group.

Highlights - European Defence Agency - European Investment Bank agreement: committee debate - Subcommittee on Security and Defence

Retrieved on: 
Friday, July 9, 2021
European Union, Multilateral development banks, Financial services, Finance, European Investment Bank, Kris Peeters, Permanent Structured Cooperation, Common Security and Defence Policy, EIB

European Defence Agency - European Investment Bank agreement: committee debate

Key Points: 
  • European Defence Agency - European Investment Bank agreement: committee debate
    European Defence Agency - European Investment Bank agreement: committee debate
    The Subcommittee on Human Rights will discuss the cooperative financing mechanism agreement reached between the European Defence Agency and the European Investment Bank, with EIB Vice-President Kris Peeters, on 12 July.
  • Since the current rules do not allow the EIB to finance purely military projects or infrastructure, the agreement has the same ambition as the European Development Fund (EDF) and the Permanent Structured Cooperation (PESCO).

OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank

Retrieved on: 
Friday, July 9, 2021
European Union, Finance, Money, Structured finance, Multilateral development banks, Fixed-income securities, European Investment Bank, Tranche, EIB

NANTES, France, July 09, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced today a 10 million payment corresponding to the first tranche of the financing granted by the European Investment Bank (EIB).

Key Points: 
  • NANTES, France, July 09, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced today a 10 million payment corresponding to the first tranche of the financing granted by the European Investment Bank (EIB).
  • The second and third tranches, respectively of 10 million and 5 million, may be drawn at the hand of the Company, subject to the achievement of specific clinical steps.
  • This first tranche will carry a fixed interest of 5% per year paid annually, with a maturity of five years.
  • The EIB is the European Union (EU) long-term financing institution, and its shareholders are the 27 EU Member States.

BancTrust & Co. Investment Bank Announces the Appointment of Dr. Peter J. West as Non-Executive Director

Retrieved on: 
Monday, June 21, 2021
Economy, Articles, Finance, International development, Investment, Economic geography, Emerging market, Investment banking, Multilateral development banks

LONDON, June 21, 2021 /PRNewswire/ -- BancTrust & Co. Investment Bank (BancTrust), the London-based emerging markets investment bank, is pleased to announce that Dr. Peter J.

Key Points: 
  • LONDON, June 21, 2021 /PRNewswire/ -- BancTrust & Co. Investment Bank (BancTrust), the London-based emerging markets investment bank, is pleased to announce that Dr. Peter J.
  • Dr. West has over 40 years of experience in analysing emerging markets and the global economy, with a focus on Latin America.
  • Dr. West is currently Economic Advisor at EM Funding, a London-based specialist in the research and distribution of niche investment strategies.
  • BancTrust & Co. Investment Bank is a London-based investment bank specialised in Emerging Markets.

BancTrust & Co. Investment Bank Announces the Appointment of Dr. Peter J. West as Non-Executive Director

Retrieved on: 
Monday, June 21, 2021
Economy, Articles, International development, Economic geography, Emerging market, Investment, Multilateral development banks

LONDON, June 21, 2021 /PRNewswire/ -- BancTrust & Co. Investment Bank (BancTrust), the London-based emerging markets investment bank, is pleased to announce that Dr. Peter J.

Key Points: 
  • LONDON, June 21, 2021 /PRNewswire/ -- BancTrust & Co. Investment Bank (BancTrust), the London-based emerging markets investment bank, is pleased to announce that Dr. Peter J.
  • BancTrust& Co. Investment Bank Announces the Appointment of Dr. Peter J.
  • West as Non-Executive Director
    Dr. West has over 40 years of experience in analysing emerging markets and the global economy, with a focus on Latin America.
  • BancTrust & Co. Investment Bank is a London-based investment bank specialised in Emerging Markets.

CABEI Chose Yeouido for Its Korea Office

Retrieved on: 
Monday, June 21, 2021
Yeouido, International Finance Center Seoul, Seoul, Geography of South Korea, Cities in Asia, Multilateral development banks, Yeongdeungpo District

SEOUL, South Korea, June 21, 2021 /PRNewswire/ -- The Seoul Metropolitan Government (SMG) succeeded in attracting the CABEI's Korea office to the capital.

Key Points: 
  • SEOUL, South Korea, June 21, 2021 /PRNewswire/ -- The Seoul Metropolitan Government (SMG) succeeded in attracting the CABEI's Korea office to the capital.
  • To support public and private investment in regionally balanced development and economic integration, the CABEI was established in 1960 as a multilateral regional development bank.
  • The CABEI plans to open its Korean branch in the International Finance Center Seoul (IFC) in Yeouido and start to serve as a strategic partner for Korea and Central America.
  • Kim Eui-Seung, Deputy Mayor for Economic Policy, said, "The installation of the CABEI's office will be a chance for Yeouido, Seoul's financial hub, to leap forward as Asia's financial center.

Pluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank

Retrieved on: 
Tuesday, May 25, 2021
European Union, Finance, Multilateral development banks, Money, European Investment Bank, Pluristem Therapeutics, Fixed-income securities, Structured finance, EIB, Tranche, Tel Aviv Stock Exchange

(Nasdaq:PSTI) (TASE:PSTI) (the Company), a leading biotechnology company, today announced the receipt of a Disbursement Offer in the amount of 20 million (approximately $24 million) from the European Investment Bank (EIB).

Key Points: 
  • (Nasdaq:PSTI) (TASE:PSTI) (the Company), a leading biotechnology company, today announced the receipt of a Disbursement Offer in the amount of 20 million (approximately $24 million) from the European Investment Bank (EIB).
  • This disbursement the first of three tranches of funding reflects that Pluristem has achieved a key milestone in a previously announced 50 million non-dilutive financing agreement .
  • Pursuant to the EIB agreement, Pluristem expects to receive the first tranche of funds during June 2021.
  • The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States.

DGAP-News: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting

Retrieved on: 
Thursday, May 20, 2021
European Union, Multilateral development banks, Financial services, Banking, Economy of the European Union, European Fund for Strategic Investments, EFSI, Asco, European Investment Bank, GDF15, CTL-002, GDFATHER, CatalYm, CTL-002, GDFATHER, CATALYM

GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment.

Key Points: 
  • GDF-15 is a factor that is secreted by several major tumor entities and interferes with effector T cell recruitment.
  • "Our tailored \'mono-followed-by-combination\' trial design allows all participating patients to access a promising, novel antibody combination therapy from the very start of the clinical trial, resulting in great patient and Investigator interest in trial participation."\nDr.
  • "\nAn additional abstract on GDF-15 preclinical data will appear in the 2021 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology supplement.
  • CatalYm received financial support from the EIF via the EIB-EIF Co-investment Facility, backed by the European Union through the European Fund for Strategic Investments (EFSI).\n'